PMID: 29755845May 15, 2018Paper

Determination of binding affinity of molecular imaging agents for steroid hormone receptors in breast cancer

American Journal of Nuclear Medicine and Molecular Imaging
Kelley SalemAmy M Fowler

Abstract

16α-[18F]Fluoro-17β-estradiol ([18F]FES) and 21-[18F]-Fluoro-16α,17α-[(R)-(1'-α-furylmethylidene)dioxyl]-19-norpregn-4-ene-3,20-dione ([18F]FFNP) are being investigated as imaging biomarkers for breast cancer patients. Quantitative positron emission tomography (PET) reflects both total receptor content and binding affinity. To study factors that may alter radiopharmaceutical binding and impact PET accuracy, assays that can separate receptor amount from binding affinity are needed. The study purpose was to quantify the binding parameters of [18F]FES and [18F]FFNP in breast cancer. Estrogen receptor-alpha (ER) and progesterone receptor (PR) positive breast cancer cell lines (MCF-7 and T47D) were used to measure [18F]FES and [18F]FFNP binding parameters via saturation and competitive binding curves. The equilibrium dissociation constant (Kd) and total receptor density (Bmax) were determined using nonlinear regression of the saturation binding curves. Half-maximal inhibitory concentration (IC50) was determined using nonlinear regression of the competitive binding curves. Linear correlation between increasing cell number and tracer uptake was observed for both [18F]FES and [18F]FFNP (R2=0.99 and 0.91, respectively). Using [18F]FES, ...Continue Reading

Related Concepts

Related Papers

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
Mohammed A KhayumJanine Doorduin
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
Michel van KruchtenGeke A P Hospers
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
Michel van KruchtenAnna K L Reyners
© 2022 Meta ULC. All rights reserved